Drug Education
Oncology Drug Reference Sheet: Capecitabine
Capecitabine (Xeloda®) was approved by the U.S. Food and Drug Administration in 1998 as a nucleoside metabolic inhibitor with antineoplastic activity indicated for adjuvant colon cancer, metastatic colorectal cancer, and metastatic breast cancer.